CD22 and Burkitt lymphoma: Gleason et al. evaluated a BiKE and a TriKE scFv construct targeting CD16/CD19 and CD16/CD19/CD22 expressed on B-cell malignancies and showed stability of the constructs in human serum and selective killing of a Burkitt-lymphoma cell line [5].